Stockreport

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology

Galmed Pharmaceuticals Ltd. - Ordinary Shares  (GLMD) 
Last galmed pharmaceuticals ltd. - ordinary shares earnings: 3/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: galmedpharma.investorroom.com
PDF The paper re-iterates the significant anti-fibrotic effect of Aramchol 300mg BID in patients with metabolic dysfunction associated steatohepatitis (MASH)Data is confirme [Read more]